Nexalin Technology (NXL) risk factors
Item 1A of every Nexalin Technology, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors47 risks12 dropped9 reworded
The company faces continued losses, growing accumulated deficits, and risks regarding compliance with Nasdaq listing standards and internal control weaknesses. Financial disclosures updated figures for the years ended December 31, 2025 and 2024.
Filed Mar 25, 2026 - FY2024 10-K risk factors59 risks
Nexalin faces severe going concern doubts, with ongoing operating losses and a cash loss of $7,607,290 for 2024. The company relies heavily on clinical trials, third-party collaborators in China, and raising capital through equity offerings. Operations are exposed to extensive Chinese regulatory, legal, and currency conversion risks.
Filed Mar 14, 2025